Fusion Pharmaceuticals
Stock Forecast, Prediction & Price Target
Fusion Pharmaceuticals Financial Estimates
Fusion Pharmaceuticals Revenue Estimates
Fusion Pharmaceuticals EBITDA Estimates
Fusion Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.44M N/A | $1.46M 1.45% | $2.06M 41.54% | Avg: $1.26M Low: $176.92K High: $4.26M avg. -38.60% | Avg: $13.34M Low: $1.86M High: $44.86M avg. 951.37% | Avg: $18.10M Low: $2.52M High: $60.85M avg. 35.66% | Avg: $140.11M Low: $19.52M High: $470.87M avg. 673.70% |
Net Income
% change YoY
| $-81.04M N/A | $-87.61M -8.10% | $-94.89M -8.31% | Avg: $-135.56M Low: $-115.47M High: $-84.63M avg. -42.85% | Avg: $-153.19M Low: $-124.66M High: $-85.29M avg. -13.00% | Avg: $-104.17M Low: $-423.85M High: $12.38M avg. 32.00% | Avg: $-51.17M Low: $-208.23M High: $6.08M avg. 50.87% |
EBITDA
% change YoY
| $-81.38M N/A | $-87.64M -7.70% | $-97.88M -11.68% | Avg: $-253.93K Low: $-853.38K High: $-35.38K avg. 99.74% | Avg: $-2.66M Low: $-8.97M High: $-372.01K avg. -951.37% | Avg: $-3.62M Low: $-12.17M High: $-504.68K avg. -35.66% | Avg: $-28.02M Low: $-94.17M High: $-3.90M avg. -673.70% |
EPS
% change YoY
| -$1.9 N/A | -$2 -5.26% | -$1.45 27.50% | Avg: -$1.52 Low: -$1.76 High: -$1.29 avg. -4.82% | Avg: -$1.5 Low: -$1.9 High: -$1.3 avg. 1.15% | Avg: -$1.59 Low: -$6.46 High: $0.19 avg. -5.66% | Avg: -$0.78 Low: -$3.17 High: $0.09 avg. 50.87% |
Operating Expenses
% change YoY
| $83.45M N/A | $89.49M 7.23% | $99.95M 11.68% | Avg: $14.43M Low: $2.01M High: $48.51M avg. -85.55% | Avg: $151.77M Low: $21.14M High: $510.05M avg. 951.37% | Avg: $205.89M Low: $28.69M High: $691.95M avg. 35.66% | Avg: $1.59B Low: $221.98M High: $5.35B avg. 673.70% |
FAQ
What is Fusion Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 6.75% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -115.47M, average is -135.56M and high is -84.63M.
What is Fusion Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 405.53% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is $176.92K, average is $1.26M and high is $4.26M.
What is Fusion Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 10.38% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$1.76, average is -$1.52 and high is $-1.29.
What is the best performing analyst?
In the last twelve months analysts have been covering Fusion Pharmaceuticals stock. The most successful analyst is Matthew Harrison whose win rate is 100%. He has correctly predicted 1/1 price targets.